Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06643130

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hypertension Cardiovascular Diseases Dyslipidemia Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

About this study

To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with hypertension and dyslipidemia

Exclusion criteria

  • The subject not meet the specified msBP and LDL-C level

Treatment and study plan

JW0104+C2402

Drug

For 8 weeks(PO (Per Oral), QD)

Other names: NA (Not Applicable)

JW0104+C2403

Drug

For 8 weeks(PO, QD)

Other names: NA (Not Applicable)

C2402

Drug

For 8 weeks(PO, QD)

Other names: NA (Not Applicable)

Primary outcomes

  1. Change from baseline in msSBP (Systolic Blood Pressure)

    Time frame: week 8

    Check msSBP

  2. Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)

    Time frame: week 8

    Check LDL-C

Secondary outcomes

  1. change from baseline in msSBP

    Time frame: week 4

    Check msSBP

  2. Change and percent change from baseline in LDL-C

    Time frame: week 4

    Check LDL-C

Study contacts

Contact information is provided by the study sponsor or research team.

Dongryung Lee

CONTACT

[email protected]

+82-2-840-6982

Minjung Kim

CONTACT

[email protected]

+82-2-840-6861

Sponsors and collaborators

Lead sponsor

JW Pharmaceutical

Industry

Registry information

Official study title

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 16, 2024
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.